Medical anticancer treatment of lung cancer associated with comorbidities: A review

• Comorbidities are frequent in patients with lung cancer.
• Anticancer therapy has to be adapted to the patient's comorbidities.
• Comorbidities impact on anticancer treatment is poorly assessed.
• Level of evidence is often limited to experts’ opinion and to case reports.
• There is a strong need for improving our knowledge in that field.

Comorbidities are frequent in patients with lung cancer, who are often treated with systemic anticancer therapy. The purpose of the present review is to report the adaptations recommended for the various drugs used in lung cancer treatment, in the context of a specific comorbidity. The literature was reviewed for neurologic, endocrine, hepatic, renal, digestive, cardiovascular, pulmonary, blood and systemic diseases. The comorbidities impact on the systemic anticancer treatment is poorly assessed. There are no good data with a high level of evidence and literature is often limited to experts’ opinion and to case reports. We need to improve our knowledge about those patients by adequate multicentric and prospective studies and registries in order to offer them better care in term of evidence-based medicine.